International Journal of Molecular Medical Science, 2025, Vol.15, No.6, 253-262 http://medscipublisher.com/index.php/ijmms 261 Meir Y., Tsaban G., Rinott E., Zelicha H., Schwarzfuchs D., Gepner Y., Rudich A., Shelef I., Blüher M., Stumvoll M., Ceglarek U., Isermann B., Klöting N., Keller M., Kovacs P., Qi L., Wang D., Liang L., Hu F., Stampfer M., and Shai I., 2025, Individual response to lifestyle interventions: a pooled analysis of three long-term weight loss trials, European Journal of Preventive Cardiology, 32(16): 1660-1670. https://doi.org/10.1093/eurjpc/zwaf308 Moiz A., Filion K., Toutounchi H., Tsoukas M., Yu O., Peters T., and Eisenberg M., 2025, Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes, Annals of Internal Medicine, 178: 199-217. https://doi.org/10.7326/annals-24-01590 Moiz A., Filion K., Tsoukas M., Yu O., Peters T., and Eisenberg M., 2025, Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation, The American Journal of Medicine, 138(6): 934-940. https://doi.org/10.1016/j.amjmed.2025.01.021 Nadeem D., Taye M., Still M., McShea S., Satterfield D., Dove J., Wood G., Addissie B., Diehl D., Johal A., Khara H., Confer B., and Still C., 2024, Effects of glucagon-like peptide-1 receptor agonists on upper endoscopy in diabetic and non-diabetic patients, Gastrointestinal Endoscopy, 100(4): 745-749. https://doi.org/10.1016/j.gie.2024.04.2900 O Olukorode J., Orimoloye D., Nwachukwu N., Onwuzo C., Oloyede P., Fayemi T., Odunaike O., Ayobami-Ojo P., Divine N., Alo D., and Alex C., 2024, Recent advances and therapeutic benefits of glucagon-like peptide-1 (GLP-1) agonists in the management of type 2 diabetes and associated metabolic disorders, Cureus, 16(10): e72080. https://doi.org/10.7759/cureus.72080 Petroni M., Brodosi L., Marchignoli F., Sasdelli A., Caraceni P., Marchesini G., and Ravaioli F., 2021, Nutrition in patients with type 2 diabetes: present knowledge and remaining challenges, Nutrients, 13(8): 2748. https://doi.org/10.3390/nu13082748 Popoviciu M., Păduraru L., Yahya G., Metwally K., and Cavalu S., 2023, Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials, International Journal of Molecular Sciences, 24(13): 10449. https://doi.org/10.3390/ijms241310449 Ren Y., Chen Y., Zheng W., Kong W., Liao Y., Zhang J., Wang M., and Zeng T., 2025, The effect of GLP‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: a systematic review and meta‐analysis, Diabetes, 27: 3607-3626. https://doi.org/10.1111/dom.16366 Sheth K., Kim S., Porterfield L., Virani S., Wadhwani S., and Vaughan E., 2025, The expanding scope of GLP-1 receptor agonists: six uses beyond diabetes, Current Atherosclerosis Reports, 27(1): 76. https://doi.org/10.1007/s11883-025-01319-6 Urva S., O'Farrell L., Du Y., Loh M., Hemmingway A., Qu H., Alsina-Fernandez J., Haupt A., Milicevic Z., and Coskun T., 2023, The novel GIP GLP‐1 and glucagon receptor agonist retatrutide delays gastric emptying, Diabetes, 25: 2784-2788. https://doi.org/10.1111/dom.15167 Ussher J., and Drucker D., 2023, Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action, Nature Reviews Cardiology, 20: 463-474. https://doi.org/10.1038/s41569-023-00849-3 Vilsbøll T., Christensen M., Junker A., Knop F., and Gluud L., 2012, Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials, The BMJ, 344: d7771. https://doi.org/10.1136/bmj.d7771 Wen Z., Sun W., Wang H., Chang R., Wang J., Song C., Zhang S., Ni Q., and An X., 2025, Comparison of the effectiveness and safety of GLP-1 receptor agonists for type 2 diabetes mellitus patients with overweight/obesity: a systematic review and network meta-analysis, Diabetes Research and Clinical Practice, 222: 111999. https://doi.org/10.1016/j.diabres.2025.111999 West J., Li M., Wong S., Le G., Teopiz K., Valentino K., Dri C., and McIntyre R., 2025, Are glucagon-like peptide-1 (GLP-1) receptor agonists central nervous system (CNS) penetrant: a narrative review, Neurology and Therapy, 14: 1157-1166. https://doi.org/10.1007/s40120-025-00724-y Wexler D., Garvey W., Ghosh A., Kazemi E., Krause-Steinrauf H., Ahmann A., Brown-Friday J., Casula S., Cherrington A., Elasy T., Fortmann S., Krakoff J., Mudaliar S., Tiktin M., and Younes N., 2025, Weight gain was associated with worsening glycemia and cardiovascular and kidney outcomes in patients with type 2 diabetes independent of diabetes medication in the GRADE randomized controlled trial, Diabetes Care, 48(6): 935-944. https://doi.org/10.2337/dc24-2825 Wong H., Sim B., Teo Y., Teo Y., Chan M., Yeo L., Eng P., Tan B., Sattar N., Dalakoti M., and Sia C., 2025, Efficacy of GLP-1 receptor agonists on weight loss BMI and waist circumference for patients with obesity or overweight: a systematic review meta-analysis and meta-regression of 47 randomized controlled trials, Diabetes Care, 48(2): 292-300. https://doi.org/10.2337/dc24-1678 Xie Z., Zheng G., Liang Z., Li M., Deng W., and Cao W., 2024, Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials, Metabolism, 161: 156038. https://doi.org/10.1016/j.metabol.2024.156038 Yao H., Zhang A., Li D., Wu Y., Wang C., Wan J., and Yuan C., 2024, Comparative effectiveness of GLP-1 receptor agonists on glycaemic control body weight and lipid profile for type 2 diabetes: systematic review and network meta-analysis, The BMJ, 384: e076410.
RkJQdWJsaXNoZXIy MjQ4ODYzNA==